Rezvilutamide Improved Prostate Cancer Survival Outcomes
In patients with metastatic hormone-sensitive prostate cancer, this therapy showed better progression-free survival than bicalutamide.
Updated on Sept. 19, 2026 in Cancer
A retrospective study of patients treated between 2021 and 2024 found that rezvilutamide offered better disease control than bicalutamide for those with high-volume metastatic hormone-sensitive prostate cancer. These findings provide new real-world insights for patients managing advanced prostate cancer.
Why it matters
Understanding the comparative efficacy of these treatments is crucial for patients navigating androgen-deprivation therapy, as high-quality real-world data in this population was previously limited. This study highlights significant differences in disease progression timelines between these two options.
This retrospective study compared 50 patients in each treatment arm, finding median radiographic progression-free survival of 25.9 months for rezvilutamide versus 16.1 months for bicalutamide. While PSA response rates were higher with rezvilutamide, overall survival benefits remain under investigation.
The details
Rezvilutamide is an androgen receptor inhibitor used alongside androgen-deprivation therapy to block the hormonal signals that drive prostate cancer growth. Researchers used propensity-score matching and adjusted for treatment-era bias to compare outcomes like radiographic progression-free survival and time to castration resistance. Grade 3 or higher adverse events occurred in 26% of patients on rezvilutamide and 24% of those on bicalutamide, with central nervous system events reported in 8% and 14% of patients, respectively.
Timeline
Patients received treatments between 2021 and 2024.
Health Landscape
This study clarifies the comparative role of rezvilutamide within the established mHSPC treatment guidelines. It marks a shift in clinical understanding by providing robust, propensity-matched evidence to inform therapy selection where previous data was sparse.
These results provide important context for patients evaluating treatment options with their medical team for advanced prostate cancer. Discuss with your physician whether these findings on progression-free survival outcomes are relevant to your specific care plan.
The takeaway
Real-world evidence suggests rezvilutamide may delay disease progression more effectively than bicalutamide in specific metastatic prostate cancer populations. Always consult your oncology team to review which hormonal therapy options align best with your clinical profile and treatment goals.
Further reading
For more on evolving research in this field, visit our Cancer section.
Source note: This article includes information reported by Nature.
